Eisai Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Eisai Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Eisai Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eisai Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Eisai Co., Ltd.

The report provides overview of Eisai Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Eisai Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Eisai Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Eisai Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Eisai Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Eisai Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Eisai Co., Ltd. Snapshot 6

Eisai Co., Ltd. Overview 6

Key Information 6

Key Facts 6

Eisai Co., Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

Eisai Co., Ltd. - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Combination Treatment Modalities 15

Pipeline Products - Partnered Products 16

Pipeline Products - Out-Licensed Products 18

Eisai Co., Ltd. - Pipeline Products Glance 20

Eisai Co., Ltd. - Late Stage Pipeline Products 20

Eisai Co., Ltd. - Clinical Stage Pipeline Products 23

Eisai Co., Ltd. - Early Stage Pipeline Products 26

Eisai Co., Ltd. - Drug Profiles 29

donepezil hydrochloride 29

eribulin mesylate 30

lenvatinib mesylate 36

lorcaserin hydrochloride 43

mitiglinide 47

perampanel 49

clevudine 52

mecobalamin 54

avatrombopag 55

fosravuconazole 57

lemborexant 59

BAN-2401 61

denileukin diftitox 63

E-2609 66

E-3710 67

E-7820 69

indisulam 70

Vaccine for Metastatic Melanoma 72

E-6011 73

E-6201 74

E-7449 76

golvatinib + lenvatinib 77

golvatinib tartrate 79

tazemetostat 81

donepezil hydrochloride Patch 83

E-2027 85

E-7046 86

E-7090 87

E-7389LF 88

SJ-733 89

AT-791 90

E-2072 91

E-2508 92

E-5539 93

E-6446 94

ER-358063 95

ER-410660 96

ER-886046 97

ER-901356 98

Small Molecule for Epilepsy 99

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders 100

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders 101

Small Molecule to Inhibit Cytidine Deaminase for Oncology 102

Small Molecule to Inhibit GWT1 Protein for Malaria 103

E-209 104

Small Molecules for Bacterial Infections 105

Small Molecules for Chagas Disease 106

Small Molecules for Lymphatic Filariasis and Onchocerciasis 107

Small Molecules for Malaria 108

Small Molecules for Oncology 109

Small Molecules for Tuberculosis 110

TRI-4 111

Eisai Co., Ltd. - Pipeline Analysis 112

Eisai Co., Ltd. - Pipeline Products by Target 112

Eisai Co., Ltd. - Pipeline Products by Route of Administration 119

Eisai Co., Ltd. - Pipeline Products by Molecule Type 120

Eisai Co., Ltd. - Pipeline Products by Mechanism of Action 121

Eisai Co., Ltd. - Recent Pipeline Updates 128

Eisai Co., Ltd. - Dormant Projects 164

Eisai Co., Ltd. - Discontinued Pipeline Products 166

Discontinued Pipeline Product Profiles 166

Eisai Co., Ltd. - Company Statement 171

Eisai Co., Ltd. - Locations And Subsidiaries 172

Head Office 172

Other Locations & Subsidiaries 172

Appendix 176

Methodology 176

Coverage 176

Secondary Research 176

Primary Research 176

Expert Panel Validation 176

Contact Us 176

Disclaimer 177

List of Tables

List of Tables

Eisai Co., Ltd., Key Information 10

Eisai Co., Ltd., Key Facts 10

Eisai Co., Ltd. – Pipeline by Indication, 2016 12

Eisai Co., Ltd. – Pipeline by Stage of Development, 2016 17

Eisai Co., Ltd. – Monotherapy Products in Pipeline, 2016 18

Eisai Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 19

Eisai Co., Ltd. – Partnered Products in Pipeline, 2016 20

Eisai Co., Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 21

Eisai Co., Ltd. – Out-Licensed Products in Pipeline, 2016 22

Eisai Co., Ltd. – Out-Licensed Products/ Combination Treatment Modalities, 2016 23

Eisai Co., Ltd. – Pre-Registration, 2016 24

Eisai Co., Ltd. – Filing rejected/Withdrawn, 2016 25

Eisai Co., Ltd. – Phase III, 2016 26

Eisai Co., Ltd. – Phase II, 2016 27

Eisai Co., Ltd. – Phase I, 2016 28

Eisai Co., Ltd. – Preclinical, 2016 30

Eisai Co., Ltd. – Discovery, 2016 32

Eisai Co., Ltd. – Pipeline by Target, 2016 117

Eisai Co., Ltd. – Pipeline by Route of Administration, 2016 123

Eisai Co., Ltd. – Pipeline by Molecule Type, 2016 124

Eisai Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 125

Eisai Co., Ltd. – Recent Pipeline Updates, 2016 132

Eisai Co., Ltd. – Dormant Developmental Projects,2016 168

Eisai Co., Ltd. – Discontinued Pipeline Products, 2016 170

Eisai Co., Ltd., Subsidiaries 176

List of Figures

List of Figures

Eisai Co., Ltd. – Pipeline by Top 10 Indication, 2016 12

Eisai Co., Ltd. – Pipeline by Stage of Development, 2016 17

Eisai Co., Ltd. – Monotherapy Products in Pipeline, 2016 18

Eisai Co., Ltd. – Partnered Products in Pipeline, 2016 20

Eisai Co., Ltd. – Out-Licensed Products in Pipeline, 2016 22

Eisai Co., Ltd. – Pipeline by Top 10 Target, 2016 116

Eisai Co., Ltd. – Pipeline by Route of Administration, 2016 123

Eisai Co., Ltd. – Pipeline by Molecule Type, 2016 124

Eisai Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 125

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports